Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0113-6856 · 2 trials · 3 indications
Measured as number of events.
Measured as number of events.
| Arm | Type | Description |
|---|---|---|
| NNC0113-6856 | EXPERIMENTAL | Participants will receive NNC0113-6856 oral tablets. |
| Placebo | EXPERIMENTAL | Participants will receive NNC0113-6856 matching placebo oral tablets. |
| NNC0113-6856 (Oral Cohort) | EXPERIMENTAL | Participants will receive single oral dose of NNC0113-6856 tablets in dose escalated manner. |
| NNC0113-6856 (i.v. Cohort) | EXPERIMENTAL | Participants will receive single dose of 1.5 milligrams (mg) NNC0113-6856 intravenously (i.v.). |
| Name | Type | Description |
|---|---|---|
| NNC0113-6856 | DRUG | NNC0113-6856 will be administered as oral tablets. |
| Placebo | DRUG | NNC0113-6856 matching placebo will be administered as oral tablets. |
Inclusion Criteria: * Male or female. * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) between 21.0 and 29.9 kilograms per meter square (kg/m\^2) (both inclusive) at screening. Additional for healthy Japanese participants: * First generation ...
NNC0113-6856 is an investigational small molecule being developed by Novo Nordisk A/S. It is currently in Phase 1 clinical development for use in healthy participants and healthy volunteers. The drug is being studied to assess its safety, tolerability, and pharmacokinetics.
NNC0113-6856 is being studied for use in healthy participants and healthy volunteers. Clinical trials are evaluating its safety, tolerability, and pharmacokinetics in these populations. The drug is not yet approved and remains in early-stage clinical development.
NNC0113-6856 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting Phase 1 clinical trials to evaluate the drug's safety and tolerability in healthy participants.
NNC0113-6856 is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total enrollment of 170 participants. The drug is investigational and has not been approved by regulatory authorities.
NNC0113-6856 has been studied in two completed Phase 1 trials. NCT05521256 evaluated the drug in healthy males, and NCT06069895 investigated multiple doses in healthy participants, including a subset of healthy Japanese participants. Both trials were conducted in Germany.
NNC0113-6856 is the primary name for this investigational drug. No alternative names have been reported in clinical trial records. It is a small molecule being developed by Novo Nordisk A/S.